Baltimore City Health Department

Mayor Adams, DOHMH Commissioner Dr. Vasan Launch ‘TeenSpace’ With Talkspace, Tele-mental Health Service For NYC Teens

Retrieved on: 
Wednesday, November 15, 2023
Mobile, Wireless, Family, Telemedicine, Virtual Medicine, Consumer Electronics, Consumer, Mental Health, Apps, Applications, Technology, State, Local, Health Technology, Teens, Health, Public Policy, Government, Mental Hygiene, Violence, City, Talkspace, The Door, Suicidal ideation, Mental health, Commissioner, DYCD, Door, Community development, Anxiety, Baltimore City Health Department, Social environment, Digital health, Depression, Student, System, Community, Partnership, Social, Community mental health service, Health department, Black, Education, New Yorker, Hope, COVID-19, Self-harm, School, JED, Mindfulness, Suicide, Mental, Residential child care community, Mobile phone, Birth control, Nursing

The launch delivers on a key commitment from Mayor Adams’ “ Working People’s Agenda ” and “ Care, Community, Action, ” his mental health plan for New York City released in March.

Key Points: 
  • The launch delivers on a key commitment from Mayor Adams’ “ Working People’s Agenda ” and “ Care, Community, Action, ” his mental health plan for New York City released in March.
  • That’s why today’s announcement is so important — it puts access to mental health support right in the hands of our young people.
  • “Tele-mental health can be a powerful tool to engage and address the rising need for mental health support amongst teens and young adults.
  • The COVID-19 pandemic has significantly amplified mental health challenges among our youth, making accessible mental health care more vital than ever.

Research Study Available in Baltimore for Lesser-Known ‘Bad’ Cholesterol Called Lp(a)

Retrieved on: 
Monday, September 18, 2023
Research, FDA, Diabetes, Clinical Trials, Cardiology, Other Health, Biotechnology, Pharmaceutical, Health, Science, Exercise, Baltimore City Health Department, Diet, Stroke, Cardiovascular disease, Weight loss, Black, Blood, Health care access among Dalits in India, Patient, LDL, Death, Pharmaceutical industry, Nursing

A cardiovascular research study is now available in Baltimore, Md., for an investigational treatment to help patients with elevated lipoprotein (a), known as Lp(a).

Key Points: 
  • A cardiovascular research study is now available in Baltimore, Md., for an investigational treatment to help patients with elevated lipoprotein (a), known as Lp(a).
  • View the full release here: https://www.businesswire.com/news/home/20230913595402/en/
    Lp(a) is similar to “bad” LDL cholesterol, but has an extra protein that hangs off LDL cholesterol particles.
  • Care Access opened its Baltimore location in collaboration with local community leaders and healthcare providers seeking to make clinical research more accessible to the Baltimore community.
  • With a global network of over 150 research sites, Care Access supports research studies conducted by 14 of the top 20 biopharmaceutical companies.

Leading Health Care Expert Named AHIP Chief Health Equity Officer

Retrieved on: 
Monday, July 24, 2023
Public Policy, Government, Healthcare Reform, Health, Consumer, African American, Health Insurance, Baltimore City Health Department, CMS, American Diabetes Association, Gender identity, Advocacy, Centers for Medicare & Medicaid Services, Disability, LaShawn, Health equity, Public, Public policy, Human, Multimedia, Office of Minority Health, Health insurance marketplace, CHIP, Public health, Johns Hopkins University, AHIP, Office, Medical school, Policy, Research, MPH, Congressional Black Caucus, Medical degree, International health, Geography, Nursing, Pharmaceutical industry, Hospital, Medicaid, Medicare, MD

With that commitment, AHIP is pleased to announce that LaShawn McIver, MD, MPH, has been named Chief Health Equity Officer, effective immediately.

Key Points: 
  • With that commitment, AHIP is pleased to announce that LaShawn McIver, MD, MPH, has been named Chief Health Equity Officer, effective immediately.
  • In this position, Dr. McIver will lead AHIP’s health equity initiatives, setting and driving strategies to improve health equity for underrepresented and medically underserved communities.
  • View the full release here: https://www.businesswire.com/news/home/20230724316087/en/
    LaShawn McIver, MD, MPH, has been named Chief Health Equity Officer of AHIP (Photo: Business Wire)
    “Inequities and disparities continue to impact millions of Americans,” said Eyles.
  • “I am driven by ensuring that health equity becomes a natural part of how we think about and deliver health care.

Harm Reduction Therapeutics and Catalent Sign Commercial Supply Agreement for Naloxone Nasal Spray to Reverse Opioid Overdoses

Retrieved on: 
Thursday, March 23, 2023
Emergency, Doctor of Philosophy, Naloxone, Baltimore City Health Department, New Drug Application, Pharmacy, Harm reduction, Patient, OTC, Entrepreneurship, Nasal spray, Catalent, FDA, Therapy, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Health department, Pharmaceutical industry

PITTSBURGH, PA and SOMERSET, N.J., March 23, 2023 /PRNewswire-PRWeb/ -- Harm Reduction Therapeutics, a 501(c)(3) non-profit pharmaceutical company whose mission is to prevent opioid overdose deaths by making low-cost naloxone available to everyone, and Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the signing of a commercial supply agreement. Under its terms, Catalent will manufacture Harm Reduction Therapeutics' naloxone nasal spray, RiVive™ (3.0 mg), for the emergency treatment of known or suspected opioid overdose.

Key Points: 
  • Under its terms, Catalent will manufacture Harm Reduction Therapeutics' naloxone nasal spray, RiVive™ (3.0 mg), for the emergency treatment of known or suspected opioid overdose.
  • PITTSBURGH, PA and SOMERSET, N.J., March 23, 2023 /PRNewswire-PRWeb/ -- Harm Reduction Therapeutics, a 501(c)(3) non-profit pharmaceutical company whose mission is to prevent opioid overdose deaths by making low-cost naloxone available to everyone, and Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the signing of a commercial supply agreement.
  • Under its terms, Catalent will manufacture Harm Reduction Therapeutics' naloxone nasal spray, RiVive™ (3.0 mg), for the emergency treatment of known or suspected opioid overdose.
  • The commercial supply agreement comes after the U.S. Food and Drug Administration (FDA) granted Harm Reduction Therapeutics Priority Review status on December 26, 2022, for its over-the-counter (OTC) naloxone nasal spray New Drug Application.

Nomi Health’s Baltimore Clinic Moves to New Location

Retrieved on: 
Monday, February 27, 2023
Biotechnology, Pharmaceutical, Medical Supplies, General Health, Health, COVID-19, Infectious Diseases, Hospitals, Baltimore City Health Department, Vaccination, Partnership, PCR, Patient, Vaccine, Pharmaceutical industry, Mpox

WHO/WHAT: Nomi Health , the direct healthcare company making it easy to access high-quality affordable care across the U.S., is moving its clinic to a new location.

Key Points: 
  • WHO/WHAT: Nomi Health , the direct healthcare company making it easy to access high-quality affordable care across the U.S., is moving its clinic to a new location.
  • In addition to offering Mpox (monkeypox) vaccinations in partnership with the Baltimore City Health Department, the clinic will continue to provide Antigen, PCR and Rapid PCR Covid testing.
  • Appointments for both first and second doses of the Mpox vaccination may be made here .
  • The clinic will also accept walk-in patients.

City of Miami Partners With Simplicity App

Retrieved on: 
Friday, September 16, 2022
CXO, Baltimore City Health Department, City, Growth, Emergency, Social media, CTO, Silicon, Communication, Simplicity, Mobile phone, San Francisco Bay Area

MIAMI, Sept. 16, 2022 /PRNewswire/ -- Simplicity Tech Inc. announces today that the City of Miami has added Simplicity to its list of social networks to enhance the way it communicates with residents. With the Simplicity app, Miami residents can access a range of important city information in English or Spanish in a single app.

Key Points: 
  • MIAMI, Sept. 16, 2022 /PRNewswire/ -- Simplicity Tech Inc. announces today that the City of Miami has added Simplicity to its list of social networks to enhance the way it communicates with residents.
  • With the Simplicity app, Miami residents can access a range of important city information in English or Spanish in a single app.
  • Simplicity app is a "city in your phone" where people can see all critical city updates, emergencies, outages, road closures, city events, and more.
  • The city of Cleveland, the City of Denver, and other major cities are launching the app in the upcoming months.

Harm Reduction Therapeutics Signs Commercial Supply Agreement for Fast Tracked Naloxone Nasal Spray to Reverse Opioid Overdoses

Retrieved on: 
Thursday, August 11, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmacy, HRT, Nasal spray, Emergency, Therapy, Health department, OTC, Drug development, Baltimore City Health Department, Harm reduction, Naloxone, Fast Track, Food, Entrepreneurship, Pharmaceutical industry

Under its terms, the contract manufacturer will produce Harm Reduction Therapeutics' nasal spray, RiVive (3.0mg naloxone), for the emergency treatment of known or suspected opioid overdose.

Key Points: 
  • Under its terms, the contract manufacturer will produce Harm Reduction Therapeutics' nasal spray, RiVive (3.0mg naloxone), for the emergency treatment of known or suspected opioid overdose.
  • The commercial supply agreement comes after the U.S. Food and Drug Administration (FDA) recently granted Harm Reduction Therapeutics Fast Track designation on July 1, 2022, for their OTC naloxone nasal spray, which is currently in development.
  • "This commercial supply agreement and the FDA's Fast Track designation mark major milestones for Harm Reduction Therapeutics and are significant steps forward in making OTC naloxone a reality," said Dr. Michael Hufford, Co-Founder and Chief Executive Officer at Harm Reduction Therapeutics.
  • Harm Reduction Therapeutics (HRT), Inc. is a 501(c)(3) non-profit pharmaceutical company whose mission is to prevent opioid overdose deaths by making free or low-cost over-the-counter naloxone available to everyone.

Survey Launched to Understand the Pandemic's Impact on Mental Health & Substance Use

Retrieved on: 
Friday, May 20, 2022
Solution, COVID-19, Community, Vaccination, Tacoma–Pierce County Health Department, Partnership, Substance abuse, Compliance, Safety, Organization, Health department, School, Baltimore City Health Department, Mental health, Collection, CEO, Pharmaceutical industry

BALTIMORE, May 20, 2022 /PRNewswire/ -- The St. Mary's County Health Department (SMCHD) is assessing how the COVID-19 pandemic has impacted St. Mary's County community members' mental health and substance use, or behavioral health.

Key Points: 
  • BALTIMORE, May 20, 2022 /PRNewswire/ -- The St. Mary's County Health Department (SMCHD) is assessing how the COVID-19 pandemic has impacted St. Mary's County community members' mental health and substance use, or behavioral health.
  • Aggregate data will be used to help local behavioral health providers and community organizations expand their services as needed and develop new support resources for residents.
  • "The COVID-19 pandemic has had a major impact on all of our lives in many ways," said Dr. Meena Brewster, St. Mary's County Health Officer.
  • "We are thankful for our partnership with WellCheck to better understand how the past couple years have affected mental health and use of drugs within our community.

New York City Partners with Alto Pharmacy to Distribute COVID-19 Antivirals

Retrieved on: 
Tuesday, December 28, 2021
Practice Management, Other Health, Health, General Health, State, Local, Women, Seniors, Men, Infectious Diseases, Public Policy, Government, Consumer, COVID-19, Molnupiravir, Patient, City, Park Avenue, Health, FDA, Death, Baltimore City Health Department, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Partnership, Transport, Industry, Pharmacy, Prescription, NPS, Health department, Pharmaceutical industry, Online shopping, Note

Alto Pharmacy (Alto), a patient-centric telehealth pharmacy, and the New York City Health Department announced today that they will partner to distribute the citys anticipated supply of COVID-19 oral antiviral medications, recently granted Emergency Use Authorization by the U.S Food and Drug Administration (FDA).

Key Points: 
  • Alto Pharmacy (Alto), a patient-centric telehealth pharmacy, and the New York City Health Department announced today that they will partner to distribute the citys anticipated supply of COVID-19 oral antiviral medications, recently granted Emergency Use Authorization by the U.S Food and Drug Administration (FDA).
  • Alto will serve as the exclusive provider of the citys supply of antiviral pills until supply increases sufficiently to stock multiple pharmacy partners.
  • Altos same-day courier delivery model ensures that New York City residents can have access to the medication regardless of location, transportation, or other limitations.
  • I want to thank Alto Pharmacy for partnering with the City to quickly deliver these lifesaving treatments to New Yorkers.

NOVA ScriptsCentral Selected as a 2021 Health Quality Innovator of the Year

Retrieved on: 
Friday, December 17, 2021
Organization, NOVA, Pharmacy, Hospital, Government, Education, Pharmacist, HQI, Volunteering, Medicare, Health, COVID-19, Health equity, Vaccine, NSC, Confusion, Research, Center, Patient, Baltimore City Health Department, Mark (given name), Health literacy, Disability, Prescription, Animal, Pharmaceutical industry

FALLS CHURCH, Va., Dec.17, 2021 /PRNewswire-PRWeb/ --NOVA ScriptsCentral has been recognized as a Health Quality Innovator for 2021.

Key Points: 
  • FALLS CHURCH, Va., Dec.17, 2021 /PRNewswire-PRWeb/ --NOVA ScriptsCentral has been recognized as a Health Quality Innovator for 2021.
  • The Health Quality Innovator Awards is the annual awards program created by Health Quality Innovators (HQI) that recognizes and celebrates organization's that are using successful, evidence-based approaches to quality improvement.
  • NOVA ScriptsCentral was selected as a runner up in the Health Equity category for its COVID-19 health literacy efforts as part of its Educate Before You Medicate program.
  • "We're incredibly proud that our organizations efforts to provide culturally competent COVID-19 education has led us to be recognized as a 2021 Health Quality Innovator of the Year," said Donney John, Executive Director, NOVA ScriptsCentral.